Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders Nov 26, 2024 08:30AM
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek Nov 5, 2024 08:30AM
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss Oct 21, 2024 08:30AM
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the Worl Oct 16, 2024 08:30AM
Veru to Present at the 2024 Cantor Global Healthcare Conference Sep 11, 2024 08:30AM


Aug 8, 2024 06:30AM Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
Aug 1, 2024 08:30AM Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
Jul 29, 2024 08:30AM Veru to Participate in the BTIG Virtual Biotechnology Conference
Jul 2, 2024 08:30AM Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
Jun 24, 2024 08:30AM Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
Jun 18, 2024 04:05PM Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
Jun 17, 2024 04:45PM Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
Jun 10, 2024 08:30AM Veru to Present at the American Diabetes Association's 84th Scientific Sessions
May 22, 2024 08:30AM Veru to Present at the Jefferies Global Healthcare Conference
May 15, 2024 08:32AM Veru, Inc. (VERU) Appoints Steven B. Heymsfield as the Principal Investigator for Enobosarm Phase 2b Trial for High Quality Weight Loss
May 15, 2024 08:30AM Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
May 14, 2024 08:30AM Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
May 8, 2024 06:30AM Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
Oct 4, 2023 08:32AM Veru (VERU) Reports Muscle Data from 5 Clinical Studies of Enobosarm
Oct 4, 2023 08:30AM Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Wei
Sep 26, 2023 08:31AM Veru (VERU) Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral ARDS
Sep 26, 2023 08:30AM Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Sep 20, 2023 08:30AM Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
Sep 11, 2023 07:02AM Veru, Inc. (VERU) Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm
Sep 11, 2023 07:00AM Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Aug 30, 2023 08:30AM Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
Aug 10, 2023 06:30AM Veru Reports Fiscal 2023 Third Quarter Financial Results
Jan 29, 2023 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
Jan 23, 2023 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
Jan 18, 2023 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
Jan 8, 2023 09:03PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bird, Generac, Veru, and Gap and Encourages Investors to Contact the Firm
Jan 3, 2023 09:02PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and F45 Training and Encourages Investors to Contact the Firm
Dec 12, 2022 11:51PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, and F45 Training and Encourages Investors to Contact the Firm
Dec 7, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, and Veru and Encourages Investors to Contact the Firm
Dec 2, 2022 08:55PM Bragar Eagel & Squire, P.C. Is Investigating Veru, Twist, and Leidos and Encourages Investors to Contact the Firm
Nov 27, 2022 08:45PM Bragar Eagel & Squire, P.C. Is Investigating Veru, Twist, Leidos, and DLocal and Encourages Investors to Contact the Firm
Nov 21, 2022 08:50PM Bragar Eagel & Squire, P.C. Is Investigating Fox, Instil, Veru, and Twist and Encourages Investors to Contact the Firm